Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene
Yu Du,Li Yang,Shanshan Qi,Zhi Chen,Ming Sun,Min Wu,Bin Wu,Fang Tao,Hao Xiong
DOI: https://doi.org/10.1097/mph.0000000000002822
2024-02-29
Journal of Pediatric Hematology/Oncology
Abstract:Childhood acute myeloid leukemia (AML) shows remarkable cytogenetic and molecular heterogeneity. Although most children with AML harbor identifiable chromosomal abnormalities, ~20% of them lack notable cytogenetic alterations. 1 acute megakaryocytic leukemia (AMKL) accounts for ~5% to 15% of cases of AML in children, 2–4 including Down syndrome (DS)–AMKL and non – DS-AMKL. Compared with other AML subtypes, non–DS-AMKL has inferior outcomes and higher recurrence rates, with overall and event-free survival rates of 40% to 60% and 40% to 50%, respectively. 5–7 The advent of large-scale genome sequencing has changed genetic and molecular diagnostics for pediatric AML, particularly for non–DS-AMKL. RNA sequencing has revealed many recurrent fusion genes associated with non–DS-AMKL, including CBFA2T3-GLIS2, RBM15-MRTFA, NUP98-KDM5A, and KMT2A rearrangements. 2,7,8 In a 2012 AMKL study, genome sequencing was used to detect the CBFA2T3 - GLIS2 fusion gene as a result of cryptic chromosome 16 inversion in ~20% of children with non–DS-AMKL. 9,10 Indeed, CBFA2T3-GLIS2 is a cryptic fusion gene that cannot be identified by cytogenetics. 11 Currently, CBFA2T3 - GLIS2 is the most frequent chimeric oncogene identified in pediatric non–DS-AMKL and has never been detected in adults, 8 but it does not appear to be restricted to AMKL. 11 Nevertheless, this fusion gene defines an extremely aggressive AML subtype specific to children and has a poor prognosis, with 5-year survival ranging from 14% to 42%, 5-year event-free survival of 8% to 33%, and a cumulative incidence of recurrence of 42% to 86%, even when high-intensity chemotherapy regimens and allogeneic hematopoietic stem cell transplantation (HSCT) are employed. 2,6,7,11,12 Most researchers have suggested classifying such cases as high-risk pediatric AML and considering HSCT after the first complete remission (CR1) as the optimal strategy to prevent recurrence. 2,6,7,12,13
oncology,pediatrics,hematology